Abstract
High density lipoprotein (HDL) plays a critical physiological role in protecting the body against atherosclerosis by facilitating reverse cholesterol transport and the removal of oxidized phosphoplipids from artery walls. Apolipoprotein A-I (apoA-I) is the principal protein component of HDL that is responsible for these atheroprotective effects. We have developed an apoA-I peptide analog called D-4F, which mimics the properties of apoA-I. D-4F is synthesized from Damino acids and thus can be administered orally. In murine models of atherosclerosis, D-4F markedly reduced atherosclerotic lesions in the absence of significant changes in total plasma cholesterol or HDL cholesterol levels. These results suggested that raw values of lipoprotein quantity are not the only indicators of atherosclerotic risk; the quality of the circulating lipoproteins is also important. As atherogenesis has been shown to be strongly linked to the presence of pro-inflammatory HDL, D-4F suggests therapeutic potential for treating atherosclerosis by improving the quality of patients HDL (i.e. converting pro-inflammatory HDL to anti-inflammatory HDL in vitro). ApoA-I mimetic peptides may also prove helpful in treating other symptoms of atherosclerosis, such as endothelial dysfunction and abnormal vasorelaxation. ApoA-I mimetic peptides like D-4F indicate much promise for becoming yet another part of achieving greater cardiovascular health.
Keywords: atherosclerosis, apoa-I, hdl, ldl, cholesterol, coronary artery disease
Current Cardiology Reviews
Title: Apolipoprotein A-I Mimetic Peptides for the Treatment of Coronary Artery Disease
Volume: 1 Issue: 1
Author(s): Nicole K. Yamada
Affiliation:
Keywords: atherosclerosis, apoa-I, hdl, ldl, cholesterol, coronary artery disease
Abstract: High density lipoprotein (HDL) plays a critical physiological role in protecting the body against atherosclerosis by facilitating reverse cholesterol transport and the removal of oxidized phosphoplipids from artery walls. Apolipoprotein A-I (apoA-I) is the principal protein component of HDL that is responsible for these atheroprotective effects. We have developed an apoA-I peptide analog called D-4F, which mimics the properties of apoA-I. D-4F is synthesized from Damino acids and thus can be administered orally. In murine models of atherosclerosis, D-4F markedly reduced atherosclerotic lesions in the absence of significant changes in total plasma cholesterol or HDL cholesterol levels. These results suggested that raw values of lipoprotein quantity are not the only indicators of atherosclerotic risk; the quality of the circulating lipoproteins is also important. As atherogenesis has been shown to be strongly linked to the presence of pro-inflammatory HDL, D-4F suggests therapeutic potential for treating atherosclerosis by improving the quality of patients HDL (i.e. converting pro-inflammatory HDL to anti-inflammatory HDL in vitro). ApoA-I mimetic peptides may also prove helpful in treating other symptoms of atherosclerosis, such as endothelial dysfunction and abnormal vasorelaxation. ApoA-I mimetic peptides like D-4F indicate much promise for becoming yet another part of achieving greater cardiovascular health.
Export Options
About this article
Cite this article as:
Yamada K. Nicole, Apolipoprotein A-I Mimetic Peptides for the Treatment of Coronary Artery Disease, Current Cardiology Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573403052952356
DOI https://dx.doi.org/10.2174/1573403052952356 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Discovery and Development of Marine Natural Products with Cardiovascular Pharmacological Effects
Mini-Reviews in Medicinal Chemistry A Systematic Review of Digital and Computer-Based Alcohol Intervention Programs in Primary Care
Current Drug Abuse Reviews Serum Specific Vasopressin-Degrading Activity is Related to Blood Total Cholesterol Levels in Men but not in Women
Medicinal Chemistry Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Sutureless Aortic Valve Replacement Using Perceval S Valve
Recent Patents on Cardiovascular Drug Discovery Chymase Inhibitors
Current Pharmaceutical Design β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets The Relationship between Findings of the Cardiopulmonary Exercise Test and the Functional Class in Patients with Advanced Heart Failure Candidate for Heart Transplantation
Current Respiratory Medicine Reviews Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued) Pulmonary Hypertension and Lung Transplantation
Current Hypertension Reviews Clinical Aspects of Melatonin in the Acute Coronary Syndrome
Current Vascular Pharmacology Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure
Current Pharmaceutical Design Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
Current Topics in Medicinal Chemistry Molecular Structural Characteristics of Estrogen Receptor Modulators as Determinants of Estrogen Receptor Selectivity
Mini-Reviews in Medicinal Chemistry Increased Content of Free Phenolic Compounds and Antioxidant Activity of Grape Pomace Cultivated with Three Different β-glucosidase Fungi Producers
Current Bioactive Compounds Assessing Depression in Patients with an Acute Coronary Syndrome: A Literature Review
Current Psychiatry Reviews Human Anthrax as a Re-Emerging Disease
Recent Patents on Anti-Infective Drug Discovery Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry